UniProt Q99640
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (Q99640)
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (UniProt Q99640), EC 2.7.11.1: 25 experimental structures on GenesisL1, 17 ligands bound, 22 pockets. Binding sites, pockets, druggability and 3D…
- UniProt
- Q99640
- Protein
- Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
- EC
- 2.7.11.1
- Experimental structures
- 25
- Predicted models
- 0
- Ligands
- 17
- Pockets
- 22 · 7 records with a druggable one
Structures
25 records of Q99640 in the MolNFT archive: 25 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3P1A | Structure of human Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1… | x-ray diffraction | A | — | — |
| 3P1A | Structure of human membrane-associated tyrosine- and threonine- specific CDC2-inhibitory kinase… | x-ray diffraction | A | — | — |
| 5VCV | CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Dasatinib | x-ray diffraction | A | CL, 1N1 | — |
| 5VCV | Crystal structure of human MYT1 kinase domain in complex with dasatinib | x-ray diffraction | A | CL, 1N1 | — |
| 5VCW | Crystal structure of human MYT1 kinase domain in complex with pelitinib | x-ray diffraction | A, B | 93J, SO4 | — |
| 5VCX | Crystal structure of human MYT1 kinase domain (untreated) in complex with saracatinib | x-ray diffraction | A | H8H | 2 (best 0.71) |
| 5VCX | Crystal structure of human MYT1 kinase domain (untreated) in complex with saracatinib | x-ray diffraction | A | H8H | — |
| 5VCY | Crystal structure of human MYT1 kinase domain in complex with bosutinib | x-ray diffraction | A | DB8 | 3 (best 0.69) |
| 5VCY | Crystal structure of human MYT1 kinase domain in complex with bosutinib | x-ray diffraction | A | DB8 | — |
| 5VCZ | Crystal structure of human MYT1 kinase domain in complex with bosutinib isomer | x-ray diffraction | A | XZN | — |
| 5VD0 | Crystal structure of human MYT1 kinase domain in complex with MK1775 | x-ray diffraction | A | 8X7 | — |
| 5VD0 | Crystal structure of human MYT1 kinase domain in complex with MK1775 | x-ray diffraction | A | 8X7 | — |
| 5VD1 | Crystal structure of human MYT1 kinase domain in complex with pha- 848125 | x-ray diffraction | A | P48 | — |
| 5VD3 | Crystal structure of human MYT1 kinase domain (de-phosphorylated) in complex with saracatinib | x-ray diffraction | A | H8H | — |
| 8D6C | Crystal structure of human MYT1 kinase domain bounded with compound 28 | x-ray diffraction | A, B | SO4, QGR | — |
| 8D6D | Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39 | x-ray diffraction | A, B | SO4, QGY | 7 (best 0.72) |
| 8D6D | Crystal structure of human MYT1 kinase domain bounded with compound 39 | x-ray diffraction | A, B | SO4, QGY | — |
| 8D6E | Crystal Structure of Human Myt1 Kinase domain Bounded with RP-6306 | x-ray diffraction | B, A | SO4, QGI | — |
| 8D6E | Crystal structure of human MYT1 kinase domain bounded with rp-6306 | x-ray diffraction | B, A | SO4, QGI | — |
| 8D6F | Crystal structure of human MYT1 kinase domain bounded with eph receptor inhibitor / compound 41 | x-ray diffraction | B, A | SO4, QG5 | — |
| 8WJY | PKMYT1_Cocrystal_Cpd 4 | x-ray diffraction | A | W9X | 3 (best 0.69) |
| 8ZTX | Crystal Structure of Human Myt1 Kinase domain Bounded with compound 6b | x-ray diffraction | A | A1D83 | 2 (best 0.67) |
| 8ZUD | Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8f | x-ray diffraction | A | A1D82 | 4 (best 0.69) |
| 8ZUL | Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8m | x-ray diffraction | A | A1D84 | 1 (best 0.68) |
| Q99640 | AlphaFold monomer V2.0 prediction for membrane-associated tyrosine- and threonine-specific… | — | — | — |
Ligands
- SO4 · Sulfate ion · in 7 records
- H8H · N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine · in 3 records
- 1N1 · N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide · in 2 records
- 8X7 · 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one · in 2 records
- CL · Chloride ion · in 2 records
- DB8 · 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile · in 2 records
- QGI · (1P)-2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide · in 2 records
- QGY · (1P)-2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide · in 2 records
- 93J · (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide · in 1 record
- A1D82 · 2-azanyl-3-(2,6-dimethyl-3-oxidanyl-phenyl)-5-(2-morpholin-4-ylpyridin-4-yl)benzamide · in 1 record
- A1D83 · 2-azanyl-3-(2,6-dimethyl-3-oxidanyl-phenyl)-5-pyridin-4-yl-benzamide · in 1 record
- A1D84 · 2-azanyl-5-[2-[(3~{R})-3-azanylpyrrolidin-1-yl]pyridin-4-yl]-3-(2,6-dimethyl-3-oxidanyl-phenyl)benzamide · in 1 record
- P48 · N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide · in 1 record
- QG5 · (1M)-2-amino-1-(5-hydroxy-2-methylphenyl)-1H-pyrrolo[2, 3-b]quinoxaline-3-carboxamide · in 1 record
- QGR · (1P)-2-amino-6-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide · in 1 record
- W9X · [6-azanyl-5-(2,6-dimethyl-3-oxidanyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazin-7-yl]-(6,7-dihydro-4~{H}-pyrazolo[1,5-a]pyrazin-5-yl)methanone · in 1 record
- XZN · 4-[(3,5-dichloro-4-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.